Tuesday, 31 July 2007

Management Moves At Med BioGene

MedBiogene (MBI - TSX V) has announced that Dr. Nathan Yoganathan, MBI’s founder, President and Chief Scientific Officer has transitioned to a senior advisory role as Chief Scientific Advisor. Dr. Bradley McLean, a senior scientist with MBI, has been appointed Chief Scientific Officer.

Prior to joining MBI in early 2007, Dr. McLean led the research and development of a prodrug at Twinstrand Therapeutics Inc., a clinical stage biotechnology company, to specifically target late-stage prostate cancer and the development of a chemically modified (PEGylated) variant of Twinstrand’s lead cancer therapeutic. Prior to joining Twinstrand, Dr. McLean was a post-doctoral fellow at the British Columbia Research Institute for Children’s and Women’s Health and InphoGene BioCommunications Inc. a private genomics and bioinformatics company, undertaking research into Ewings sarcoma, a rare pediatric cancer. Dr. McLean holds a B.Sc. (Hons.) and an M.Sc. from Queen’s University and a Ph.D. from the University of British Columbia.

To read the news release click here.